Targeting cysteine protease B to discover antileishmanial drugs: Directions and advances.

Leishmaniasis is a severe disease and results in high mortality rates. Despite this, there are few drugs to treat and with various limitations such as toxicity and resistance, which justifies the search for new drugs. Thus, cysteine protease B (CPB) is a promising target against leishmania due to its immunomodulatory function related to the parasite's virulence and its interaction with the host.

Current trends to design antimalarial drugs targeting -myristoyltransferase.

Malaria is a disease caused by spp., of which and are the most prevalent. Unfortunately, traditional and some current treatment regimens face growing protozoan resistance.